Ceftriaxone for treatment of ALS

• A clinical trial that may slow the progression of disease.

• Now enrolling
• Diagnosed with ALS
• Vital capacity (breathing) at least 60% of normal
• IV Drug administered through an implanted catheter
• Monthly study visits

Arimoclomol in SOD1 Positive Familial ALS (jointly funded by ALSA and FDA)

• A clinical trial of a new drug in SOD1 positive familial ALS

• Enrollment is open
• Diagnosed with familial ALS
• Genetic change in SOD1 gene or uncertain SOD1 gene status
• Many study visits in your home

Margaret Walker
404-712-8578
mlwalke@emory.edu

Arimoclomol Clinical Trial Information
sod1@emory.edu